Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent escalations in regional nuclear threats [1][3]. Group 1: Collaboration Agreement - The collaboration agreement is effective for an initial period of three years, with the possibility of a three-year extension [1]. - Pluri will produce and supply PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9]. - The collaboration aims to secure external funding to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5]. Group 2: Strategic Goals - The collaboration addresses Ukraine's urgent need for radiation countermeasures and ensures secure storage and rapid deployment of treatments [8]. - It seeks to attract public and private funding to support the development and accessibility of PLX-R18 [9]. - The collaboration may potentially generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5]. Group 3: Context and Need - The collaboration is a response to recent incidents, including a Russian drone strike on the Chernobyl nuclear power plant, highlighting the need for effective radiation countermeasures [3]. - H-ARS is caused by exposure to high levels of ionizing radiation, leading to severe health risks [6].

As filed with the Securities and Exchange Commission on April 3, 2024 Registration No.________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORMS-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIORESTORATIVE THERAPIES, INC. (Exact name of registrant as specified in its charter) 40 Marcus Drive, Suite One Melville, New York 11747 (631) 760-8100 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) La ...